Rilmenidine treatment in hypertensive patients with cerebrovascular transient ischemic attacks

Aim. To assess effectiveness of rilmenidine treatment in arterial hypertensive (AH) patients with cerebrovascular transient ischemic attacks (TIA). Material and methods. The study included 39 patients with Stage I-III AH, combined with TIA: 6 males and 33 females; mean age 47±2.7 years. At baseline...

Full description

Saved in:
Bibliographic Details
Main Authors: A. P. Kondrakhin, G. N. Gorokhovskaya, A. I. Martynov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2005-10-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/998
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. To assess effectiveness of rilmenidine treatment in arterial hypertensive (AH) patients with cerebrovascular transient ischemic attacks (TIA). Material and methods. The study included 39 patients with Stage I-III AH, combined with TIA: 6 males and 33 females; mean age 47±2.7 years. At baseline and after 4 weeks of rilmenidine monotherapy (1 mg/d), 24-hour blood pressure monitoring (BPM) was performed; beta-adrenoreceptivity of red cell membranes (b-ARM) was measured; psychological status and quality of life (QoL) by DISS (Disability Scale) were assessed. Results. According to 24-hour BPM results, rilmenidine therapy was associated with statistically significant (р<0.01) antihypertensive effect in Stage III AH patients. In participants with Stage I-II AH, circadian BP profile (BP CP) was normalized without statistically significant BP decline. At baseline, b-ARM was increased in all patients, that could be regarded as a sign of enhanced sympatho-adrenal activity. Rilmenidine (1 mg/d) substantially reduces hypersympathicotony, manifested in b-ARM decrease during the therapy. QoL also significantly improved during rilmenidine therapy (р<0.01). Conclusion. Rilmenidine reduced BP level, benefited BP CP, decreased sympathicoadrenal system activity, and improved QoL in AH patients with TIA.
ISSN:1728-8800
2619-0125